1. Early treatment of HER2-amplified brain tumours with targeted nk-92 cells and focused ultrasound improves survival. (3rd June 2015) Authors: Alkins, RD; Burgess, A; Kerbel, R; Wels, WS; Hynynen, K Journal: Canadian journal of neurological sciences Issue: Volume 42:(2015)Supplement 1 Page Start: S11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P06.12 Combination therapy of CAR-NK-cells and anti-PD-1 antibody results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo. (1st October 2020) Authors: Strassheimer, F; Strecker, MI; Alekseeva, T; Macas, J; Demes, MC; Mildenberger, IC; Tonn, T; Wild, PJ; Sevenich, L; Reiss, Y; Harter, PN; Plate, KH; Wels, WS; Steinbach, JP; Burger, MC Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 2 Page Start: A46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P06.13 A novel local treatment approach? Targeted immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors through locally administered HER2-AAVs in combination with CAR-NK cells. (1st October 2020) Authors: Strecker, MI; Strassheimer, F; Reul, J; Harter, PN; Tonn, T; Steinbach, JP; Wels, WS; Buchholz, CJ; Burger, MC Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 2 Page Start: A47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗